Broad use of the SPECTROstar Nano in Anticancer Drug Development

March 22, 2012

Dr. Candida Perera, Cornerstone Pharmaceuticals, Inc., USA - Runner up in BMG LABTECH's SPECTROstar Nano competition

Dr. Edward Dell | BMG LABTECH
Dr. EJ Dell
PhD, Sales Manager Northwest
BMG LABTECH USA

Cornerstone Pharmaceuticals, Inc. proposes to use the SPECTROstar Nano absorbance microplate reader to investigate new anticancer drugs. Their goal is to compare the metabolism of tumor cells to those of healthy cells in order to find possible drug targets that would affect quickly growing tumor cells. Concentrating on a newly found compound, CPI-613, they propose to use the SPECTROstar Nano for ELISAs to monitor the activity of different pyruvate dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatase (PDP) isoforms in the presence of the drug in different tumor and tissue samples. Cornerstone Pharmaceuticals believes that the SPECTROstar Nano will allow “for efficient and effective drug screening with the ultimate benefit being to cancer patients."

go to top